title: Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-fampridine treatment of patients with multiple sclerosis.
abstract: OBJECTIVE
  To provide distribution-based estimates of the minimal clinical important difference (MCID) after slow release fampridine treatment on cognition and functional capacity in people with MS (PwMS).
  
  
  METHODS
  MCID values were determined after SR-Fampridine treatment in 105 PwMS. Testing included the Timed 25 Foot Walk (T25FW), the Symbol Digit Modalities Test (SDMT), the Six Spot Step Test (SSST), the 9-Hole-Peg-Test (9-HPT), and the 5-Time-Sit-To-Stand test (5-STS).
  
  
  RESULTS
  MCID values: T25FW 17.8% (9.1-17.8), SDMT 17.1% (9.2-17.1), SSST 16.7% (8.5-16.7), 9-HPT 15.3% (0-15.3), and 5-STS 34.6% (16.9-34.6).
  
  
  CONCLUSIONS
  This study presents distribution-based estimates of MCID values for the SSST, the 9-HPT, and the 5-STS and confirms MCID estimates for the T25FW and the SDMT.
authors.affiliation: Institute of Regional Health Research, University of Southern Denmark, Denmark; MS-Clinic of Southern Jutland (Sønderborg, Vejle, Esbjerg), Department of Neurology, Sønderborg Hospital, Denmark. Electronic address: henrik.boye.jensen@rsyd.dk.
authors.forename: H B
authors.initials: HB
authors.lastname: Jensen
authors.affiliation: MS-Clinic of Southern Jutland (Sønderborg, Vejle, Esbjerg), Department of Neurology, Sønderborg Hospital, Denmark.
authors.forename: Sepehr
authors.initials: S
authors.lastname: Mamoei
authors.affiliation: Department of Neurology, Odense University Hospital, Denmark.
authors.forename: M
authors.initials: M
authors.lastname: Ravnborg
authors.affiliation: Department of Public Health, Section of Sport Science, Aarhus University, Denmark.
authors.forename: U
authors.initials: U
authors.lastname: Dalgas
authors.affiliation: Institute of Regional Health Research, University of Southern Denmark, Denmark; MS-Clinic of Southern Jutland (Sønderborg, Vejle, Esbjerg), Department of Neurology, Sønderborg Hospital, Denmark.
authors.forename: E
authors.initials: E
authors.lastname: Stenager
mesh_terms: D015761:4-Aminopyridine / Q000627:therapeutic use*; D001132:Arm / Q000503:physiopathology; D003071:Cognition / Q000187:drug effects*; D004185:Disability Evaluation; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D026902:Potassium Channel Blockers / Q000627:therapeutic use*; D012016:Reference Values; D016138:Walking / Q000502:physiology
chemical_list: D026902:Potassium Channel Blockers; D015761:4-Aminopyridine
keywords: Axonal loss; Change; Demyelination; MCID; Minimal clinically important difference; Multiple sclerosis; Rehabilitation